230 related articles for article (PubMed ID: 38379924)
1. Improved characterization and translation of NK cells for canine immunotherapy.
Razmara AM; Gingrich AA; Toedebusch CM; Rebhun RB; Murphy WJ; Kent MS; Canter RJ
Front Vet Sci; 2024; 11():1336158. PubMed ID: 38379924
[TBL] [Abstract][Full Text] [Related]
2. Characterization and Potential Applications of Dog Natural Killer Cells in Cancer Immunotherapy.
Gingrich AA; Modiano JF; Canter RJ
J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31717876
[TBL] [Abstract][Full Text] [Related]
3. Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target.
Gingrich AA; Reiter TE; Judge SJ; York D; Yanagisawa M; Razmara A; Sturgill I; Basmaci UN; Brady RV; Stoffel K; Murphy WJ; Rebhun RB; Brown CT; Canter RJ
Front Immunol; 2021; 12():670309. PubMed ID: 34594320
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer and T Cell Infiltration in Canine Osteosarcoma: Clinical Implications and Translational Relevance.
Razmara AM; Judge SJ; Gingrich AA; Cruz SM; Culp WTN; Kent MS; Rebhun RB; Canter RJ
Front Vet Sci; 2021; 8():771737. PubMed ID: 34869744
[TBL] [Abstract][Full Text] [Related]
5. Adoptive Natural Killer Cell Immunotherapy for Canine Osteosarcoma.
Kisseberth WC; Lee DA
Front Vet Sci; 2021; 8():672361. PubMed ID: 34164452
[TBL] [Abstract][Full Text] [Related]
6. Examination of IgG Fc Receptor CD16A and CD64 Expression by Canine Leukocytes and Their ADCC Activity in Engineered NK Cells.
Hullsiek R; Li Y; Snyder KM; Wang S; Di D; Borgatti A; Lee C; Moore PF; Zhu C; Fattori C; Modiano JF; Wu J; Walcheck B
Front Immunol; 2022; 13():841859. PubMed ID: 35281028
[TBL] [Abstract][Full Text] [Related]
7. Natural Killer Cells: The Linchpin for Successful Cancer Immunotherapy.
Shaver KA; Croom-Perez TJ; Copik AJ
Front Immunol; 2021; 12():679117. PubMed ID: 33995422
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
[TBL] [Abstract][Full Text] [Related]
9. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
10. Chimeric antigen receptor-based natural killer cell immunotherapy in cancer: from bench to bedside.
Zhang B; Yang M; Zhang W; Liu N; Wang D; Jing L; Xu N; Yang N; Ren T
Cell Death Dis; 2024 Jan; 15(1):50. PubMed ID: 38221520
[TBL] [Abstract][Full Text] [Related]
11. The application of autologous cancer immunotherapies in the age of memory-NK cells.
Lizana-Vasquez GD; Torres-Lugo M; Dixon RB; Powderly JD; Warin RF
Front Immunol; 2023; 14():1167666. PubMed ID: 37205105
[TBL] [Abstract][Full Text] [Related]
12. Taking Lessons from CAR-T Cells and Going Beyond: Tailoring Design and Signaling for CAR-NK Cells in Cancer Therapy.
Ruppel KE; Fricke S; Köhl U; Schmiedel D
Front Immunol; 2022; 13():822298. PubMed ID: 35371071
[TBL] [Abstract][Full Text] [Related]
13. The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer.
Rezvani K; Rouce RH
Front Immunol; 2015; 6():578. PubMed ID: 26635792
[TBL] [Abstract][Full Text] [Related]
14. CAR-NK Cells: From Natural Basis to Design for Kill.
Khawar MB; Sun H
Front Immunol; 2021; 12():707542. PubMed ID: 34970253
[TBL] [Abstract][Full Text] [Related]
15. Cellular Immunotherapy of Canine Cancer.
Addissie S; Klingemann H
Vet Sci; 2018 Dec; 5(4):. PubMed ID: 30563208
[TBL] [Abstract][Full Text] [Related]
16. NCR1 Expression Identifies Canine Natural Killer Cell Subsets with Phenotypic Similarity to Human Natural Killer Cells.
Foltz JA; Somanchi SS; Yang Y; Aquino-Lopez A; Bishop EE; Lee DA
Front Immunol; 2016; 7():521. PubMed ID: 27933061
[TBL] [Abstract][Full Text] [Related]
17. The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors.
Piccinelli S; Romee R; Shapiro RM
Semin Hematol; 2023 Jan; 60(1):42-51. PubMed ID: 37080710
[TBL] [Abstract][Full Text] [Related]
18. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
Kennedy PR; Felices M; Miller JS
Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
[TBL] [Abstract][Full Text] [Related]
19. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.
Knapp DW; Dhawan D; Ramos-Vara JA; Ratliff TL; Cresswell GM; Utturkar S; Sommer BC; Fulkerson CM; Hahn NM
Front Oncol; 2019; 9():1493. PubMed ID: 32039002
[TBL] [Abstract][Full Text] [Related]
20. Use of multi-color flow cytometry for canine immune cell characterization in cancer.
Parys M; Bavcar S; Mellanby RJ; Argyle D; Kitamura T
PLoS One; 2023; 18(3):e0279057. PubMed ID: 36996049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
